[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Bordeaux\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":702},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,172,0,25,[9,44,75,106,132,163,187,208,233,258,290,317,343,368,396,421,448,474,504,533,559,582,608,644,669],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100652977","creation-of-a-biological-collection-of-bronchiai-and-pulmonary-tissues-from-surgical-waste-100652977",false,"NCT07780630","Creation of a Biological Collection of BRonchiaI and Pulmonary Tissues From Surgical wastE","BRISE","Inclusion Criteria:\n\n* Male or female\n* Adult or children\n* Having required or necessitating, in the context of care or research involving the human person promoted by the Bordeaux University Hospital (ARISE, BIRDIES, ICEBERG, VIRCHILLD) or by Inserm (COBRA), either thoracic surgery such as lobectomy, pneumonectomy or lung transplantation in the Thoracic Surgery Department of the Haut Lévêque Hospital, or bronchial fiberscopy with biopsies and\u002For bronchial brushing and\u002For BAL at the children's hospital of the Pellegrin Hospital or at the Haut Lévêque Hospital.\n* Having received or, for children whose holders of parental authority have received, an information note with the possibility of opposition in accordance with the MR004 (French law - Commission Nationale de l'Informatique et des Libertés (CNIL))\n\nExclusion Criteria:\n\n* Patient or holder of parental authority for children who have expressed their opposition to participation in the research",true,"ALL","1 Year","80 Years",{"count":22,"type":23},650,"ESTIMATED","1 Day","OBSERVATIONAL","The biological samples and associated data will facilitate the successful implementation of the research collaboration between Bordeaux University Hospital and the University of Bordeaux on the pathophysiology of bronchopulmonary diseases. In the longer term, this research could lead to the discovery of new therapeutic targets for asthma, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, and acute respiratory distress syndrome.",[28,29,30],"COPD (Chronic Obstructive Pulmonary Disease)","Asthma (Diagnosis)","Safe Volunteers","NOT_YET_RECRUITING","2026-08-19",{"date":34,"type":35},"2026-08-21","ACTUAL",{"date":37,"type":23},"2026-09-01",{"date":39,"type":23},"2028-12-31",{"name":41,"class":42},"University Hospital, Bordeaux","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":43},"100633234","impact-of-a-nursing-educational-consultation-on-the-patients-adherence-to-their-post-stroke-care-plan-100633234","NCT07524036","Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan.","Impact of a Nursing Consultation at the End of Hospitalization on Adherence to the Post-stroke Care Plan for Patients Admitted to the Vascular Neurology Unit","ICEIPAVC","Inclusion Criteria:\n\n* Patients admitted to the Neurovascular Unit (UNV) of CHCB for ischemic stroke and\u002For hemorrhagic stroke confirmed by brain imaging and\u002For TIA with an ABCD2 score \\>5,\n* Patients whose discharge orientation is a return home\n* Age ≥ 18 years\n* NIHSS \\\u003C 15\n* Montreal Cognitive Assessment (MoCa) \\> 21\u002F30\n* Free and informed consent signed by the patient.\n* Person affiliated with or a beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Patients admitted for mechanical thrombectomy, outside the Basque Coast Hospital (CHCB)\n* Rankin score estimated at discharge ≥ 4\n* Patients requiring assistance from a third party at home for the management of their medication or with stroke follow-up at Prado\n* Patients placed under protection measures","18 Years",{"count":54,"type":23},300,"INTERVENTIONAL",[57],"NA","This prospective, single-center, randomized study will evaluate the impact of implementing an educational nursing consultation at the end of hospitalisation for stroke patients returning home on overall adherence to stroke-related medication during the 4-month follow-up visit.",[60,61],"Stroke","Patient Education",[63,64,65],"stroke","patient education","post stroke consultation","RECRUITING","2026-08-17",{"date":69,"type":35},"2026-08-18",{"date":71,"type":35},"2026-06-11",{"date":73,"type":23},"2028-06-11",{"name":41,"class":42},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":83,"minAge":52,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":55,"phases":86,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},"100652070","phase-2-multicentre-study-evaluating-the-efficacy-of-a-7-day-course-of-doxycycline-for-the-treatment-of-asymptomatic-anal-lymphogranuloma-venereum-100652070","NCT07767422","Multicentre Study Evaluating the Efficacy of a 7-day Course of Doxycycline for the Treatment of Asymptomatic Anal Lymphogranuloma Venereum.","Multicentre Study Evaluating the Efficacy of a 7-day Course of Doxycycline for the Treatment of Asymptomatic Anal Lymphogranuloma Venereum","SHORT-LGV","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Male sex at birth\n* LGV-positive result on anal specimen using Nucleic Acid Amplification Test at screening\n* Having taken at least doxycycline for two days (i.e 400 mg of doxycycline)\n* Not having taken more than 7 days of doxycycline 200 mg per day\n* No more than 12 days between the date of sampling and date of inclusion\n* No anorectal symptoms\n* Individual available for participation and follow-up during the four weeks required for the study\n* Affiliate or beneficiary of a social security scheme\n* Free written informed consent signed by the participant or by a legal representative (in the event of the participant's inability to consent) and the investigator (no later than the day of inclusion and before any examination required by the research).\n\nExclusion Criteria:\n\n* Individual with anorectal symptoms\n* Antibiotic treatment with antichlamydial activity (fluoroquinolones, macrolides-lincosamides-streptogramins, tetracyclines and rifampicin) within 28 days before the screening visit\n* Use of doxycycline post-exposure prophylaxis (Doxy-PEP)\n* Participation in another study\n* Individual under a measure of legal protection measure (safeguard of justice, guardianship or curatorship) or unable to consent\n* Refusal to participate in the study\n* Mental state rendering the person giving consent incapable of understanding the entirety of the trial\n* Participant detained by judicial or administrative decision.\n* Individual receiving an anticoagulant therapy\n* Individual with a history of known hypersensitivity to doxycycline or any other antibiotic of the tetracycline family or allergy to any of the excipients (Hydrogenated castor oil, povidone, anhydrous colloidal silica, magnesium stearate, microcrystalline cellulose, sodium carboxymethyl starch (type A)).\n* Individual treated with retinoids by general route.\n* Individual receiving 10,000 IU of vitamin A per day or more\n* Individual being a relative of the investigator or a relative of someone from the team directly involved in the trial, including assistant doctors, pharmacists, nurses, and trial coordinators","MALE",{"count":85,"type":23},120,[87],"PHASE2","Lymphogranuloma venereum (LGV) is a sexually transmitted infection (STI) caused by the L genotypes of C. trachomatis. Proctitis is the main clinical manifestation of infection in the current LGV epidemic. However, recent European studies reported that about 25% of the anal LGV infections are asymptomatic. In France, asymptomatic anal LGV increased from 36.1% (44\u002F124) in 2020 to 52.4% (66\u002F126) in 2022. LGV testing is recommended on all C. trachomatis-positive anorectal specimens because therapy of extended duration is required. Patients with anal C. trachomatis infection should be treated initially with 7-day course of doxycycline (200 mg per day orally) while awaiting the results of LGV testing. Treatment should be extended to 21 days in cases of LGV according to current European and USA guidelines for LGV treatment. This regimen is indicated for symptomatic and asymptomatic anorectal LGV, with a 98.5% treatment efficacy. However, there is no obvious biological basis for prolonged treatment of asymptomatic LGV. Three recent retrospective studies showed that a 7-day course of doxycycline was effective for the treatment of asymptomatic LGV, with microbial cure ranging from 97% (38\u002F39) to 100% (54\u002F54). The objective of this study is to evaluate the efficacy (microbiological cure rate) of a 7-day course of doxycycline 200 mg daily orally for the treatment of asymptomatic anal LGV infection, four weeks after treatment initiation.",[90,91,92],"Lymphogranuloma Venereum","no Anorectal Symptoms","Doxycycline",[94,95,96,97],"Lymphogranuloma venereum","Chlamydia trachomatis","asymptomatic","doxycycline","2026-08-11",{"date":67,"type":35},{"date":101,"type":23},"2026-09",{"date":103,"type":23},"2027-11",{"name":41,"class":42},14,{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":43},"100650818","identification-and-description-of-patients-with-high-risk-non-metastatic-rcc-100650818","NCT07753343","Identification and Description of Patients With High-risk Non Metastatic RCC","Identification and Description of Patients With High-risk Non Metastatic RCC (UroCCR 127)","HIROES","Inclusion Criteria:\n\n* Adult patients diagnosed with local RCC or high-risk locally advanced RCC,\n* Included in UroCCR register between 1st january 2014 and 31st december 2023,\n* Consenting to participate in UroCCR and UroCCR-Chain registers.\n\nExclusion Criteria:\n\n* Patients with metastatic disease at inclusion,\n* Patients not linked between UroCCR and SNDS datasources,\n* Patients with hereditary RCC.",{"count":115,"type":23},6109,"Renal cell carcinoma (RCC) is the 14th most common cancer worldwide. Surgery is the standard of care for localized RCC, however, the risk of recurrence varies widely among patients. Adjuvant pembrolizumab has been shown to improve outcomes after nephrectomy but is associated with substantial toxicity and high costs. This study uses real-world data from the French UroCCR-Chain registry to characterize the natural history, management, and outcomes of non-metastatic RCC in France, with the aim of informing adjuvant treatment decisions",[118],"Renal Cell Carcinoma",[120,121,122,123],"renal cell carcinoma (RCC) high-risk RCC","real life","UroCCR","UroCCR-Chain","2026-08-05",{"date":126,"type":35},"2026-08-07",{"date":128,"type":35},"2026-04-17",{"date":130,"type":23},"2028-04-17",{"name":41,"class":42},{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":43},"100606305","a-study-to-better-understand-the-biological-and-molecular-mechanisms-involved-in-glioblastoma-recurrence-and-progression-100606305","NCT07173829","A Study to Better Understand the Biological and Molecular Mechanisms Involved in Glioblastoma Recurrence and Progression","A Prospective Study to Better Understand the Molecular, Immune and Metabolic Mechanisms Involved in Glioblastoma Recurrence and Progression, in the Aim to Identify New Therapeutic Targets and to Improve Current Therapies","BORDEAUX-GLIO","Inclusion Criteria:\n\n* Patients of 18 years or older, with highly suspected glioblastoma on neuro-imagery\n* Planned surgical tumor resection,\n* No objection to participate in research\n* Signed genetic consent\n\nExclusion Criteria:\n\n* Patients under guardianship, curatorship or protective supervision\n* Taking immunosuppressants\n* Pregnant or breast-feeding women\n* Patients deprived of their liberty by judicial or administrative decision, or under psychiatric care",{"count":141,"type":23},45,"BORDEAUX-GLIO is a prospective, monocentric study which will describe the molecular, immune and metabolic pathways involved in the progression and relapse of glioblastoma, using blood and tumor samples from patients who have undergone surgery for newly diagnosed or recurrent glioblastoma in the center.",[144],"Glioblastoma",[146,147,148,149,150,151,152,153,154,155],"Glioblastoma progression","Glioblastoma recurrence","Metabolism","Lactate","Metabolomic","Transcriptomic","Radiation therapy","Radiosensitizer","Immunotherapy","γδ T lymphocytes","2026-08-04",{"date":126,"type":35},{"date":159,"type":35},"2025-10-22",{"date":161,"type":23},"2031-10",{"name":41,"class":42},{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":55,"phases":172,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":184,"leadSponsor":186,"locationsCount":43},"100604404","phase-3-echo-guided-scalp-blocks-and-incidence-of-postoperative-pain-in-scheduled-supratentorial-intracranial-surgery-100604404","NCT07149077","Echo-guided Scalp Blocks and Incidence of Postoperative Pain in Scheduled Supratentorial Intracranial Surgery.","ULTRASCALP","Inclusion Criteria:\n\n* Patient managed in the neurosurgical unit for supratentorial intracranial surgery.\n* Person affiliated or beneficiary of a social security plan.\n* Free, informed, and written consent signed by the participant and the investigating physician (at the latest on the day of inclusion and before any examination required by the research).\n\nExclusion Criteria:\n\n* Surgical procedure under awake surgery (systematic realization of scalp blocks necessary)\n* Aphasia of comprehension preoperatively or expected postoperatively or any other neurological impairment making self-evaluation of pain impossible.\n* Contraindication to the use of local anesthetics: allergy or history of intoxication to local anesthetics\n* Contraindication to adrenaline infiltration: severe ventricular rhythm disorders, severe obstructive cardiomyopathy, unstable coronary insufficiency, hypersensitivity to adrenaline.\n* Chronic pain patient or patient with daily preoperative consumption of morphine\n* Pregnant or breast-feeding woman\n* Patient under legal protection (persons deprived of liberty or under guardianship)",{"count":171,"type":23},230,[173],"PHASE3","Up to 30% of patients undergoing intracranial surgery present moderate to severe pain. In this type of surgery, the restriction of the pharmacopoeia, which goes against the concept of multimodal analgesia, results in the important use of opioids not without consequences in terms of complications. Numerous studies have highlighted the benefits of scalp blocks in postoperative pain. The originality of this study lies firstly in the fact that the scalp blocks will be guided by ultrasound and secondly, the incidence of severe pain after scalp blocks will be evaluated",[176],"Anesthesia , Analgesia",[178,179,180,181],"scalp block","neurosurgery","supratentorial surgery","craniotomy",{"date":126,"type":35},{"date":101,"type":23},{"date":185,"type":23},"2028-09",{"name":41,"class":42},{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":55,"phases":196,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":203,"startDateStruct":204,"completionDateStruct":205,"leadSponsor":207,"locationsCount":43},"100554043","evaluation-of-the-effectiveness-of-extending-the-passerelle-system-for-prescribing-adapted-physical-activity-to-patients-with-type-2-diabetes-in-nouvelle-aquitaine-france-100554043","NCT06493955","Evaluation of the Effectiveness of Extending the \"Passerelle\" System for Prescribing Adapted Physical Activity to Patients With Type 2 Diabetes in Nouvelle-AQUItaine (France)","PAPA-NAQUI","Inclusion Criteria:\n\n* Patients with type 2 diabetes with initial diagnosis of fasting blood glucose \\> 1.26 g\u002Fl on 2 occasions\n* Patient aged 18 or over\n* Patient with a Marshall score ≤ 3\n* Patient residing in the Nouvelle-Aquitaine region\n* Patient eligible for the \"Passerelle\" program\n* Patient willing to participate\n* Patient agreeing to take part in the study and having signed an informed consent form\n* Person affiliated or benefiting from a social security scheme.\n\nExclusion Criteria:\n\n* Patient with any other unstabilized pathology:\n* Cardiovascular: unstable angina, stress angina, malignant hypertension, recent myocardial infarction, unstabilized heart disease\n* Pulmonary: uncontrolled asthma, COPD exacerbation\n* Endocrine: diabetes with HbA1c \\> 9%, plantar perforator disease\n* Pregnant patient\n* Diabetic patient with contraindication to APA prescription\n* Patient under court protection",{"count":195,"type":23},308,[57],"Type 2 diabetes is on the increase worldwide. Two major risk factors have been identified: overweight and physical inactivity. National and international recommendations encourage general practitioner to guide patients in changing their lifestyle. As regards physical activity in France, general practitioner have been able to prescribe adapted physical activity (APA) for their patients since 2016. In type 2 diabetes, it is known that physical activity interventions are cost-effective. However, these interventions are often too expensive and far removed from real life. It is also known that the benefits of intervention increase up to 18 months, then diminish to zero at 36 months. In Nouvelle-Aquitaine, France, the \"PEPS Sport-santé network\", offers physical activity coaching for patients who are not sufficiently active: the \"Passerelle\" program. Patients can benefit from a weekly physical activity session for 6 months.\n\nThe investigators would therefore like to assess whether extending the existing \"Passerelle program\" by 6 months, with one session every 15 days, is effective in maintaining the volume of physical activity 12 months after the end of the intervention.",[199],"Diabetes Mellitus, Type 2",[199,201,202],"Adapted Physical Activity","general practice",{"date":126,"type":35},{"date":101,"type":23},{"date":206,"type":23},"2029-09",{"name":41,"class":42},{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":17,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":55,"phases":218,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":43},"100612559","peripheral-helper-t-cells-in-common-variable-immunodeficiency-100612559","NCT07255157","Peripheral Helper T-cells in Common Variable ImmunoDeficiency","Deciphering the Role of Peripheral Helper T-cells in Common Variable ImmunoDeficiency Pathophysiology in Patients With Non-infectious Complications","TAPDI","Inclusion Criteria:\n\n* Male or female;\n* Age ≥ 18 years;\n* Standard criteria will be applied to diagnose CVID, specifically requiring: 1) low serum IgG level \\\u003C5 g\u002FL, combined with low IgM- and\u002For IgA-isotype concentrations \\\u003C0.4 g\u002FL or \\\u003C0.7 g\u002FL, respectively; 2) poor antibody responses to immunization or infection; and 3) exclusion of other defined forms of secondary hypogammaglobulinemias. Patients meeting the definitional criteria for CVID will be included, regardless of the duration of the disease or the treatment received (gammaglobulins substitution or not);\n* Being affiliated to health insurance;\n* Willing to participate and to sign informed consent.\n\nExclusion Criteria:\n\n* Patients on corticosteroids and\u002For immunosuppressants;\n* Patients with a primary immunodeficiency genetically characterized, such as Bruton disease our HyperIgM syndrome;\n* Patients with an active chronic infection;\n* Pregnant or breastfeeding women;\n* Persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent.",{"count":217,"type":23},60,[57],"The aim is to determine whether whether Tph could support non-infectious complications through providing help to pathological B-cells.",[221],"Common Variable Immunodeficiency",[223,224,225],"common variable immunodeficiency","peripheral helper T cells","B cells","2026-08-03",{"date":124,"type":35},{"date":229,"type":35},"2026-07-09",{"date":231,"type":23},"2028-01",{"name":41,"class":42},{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":257,"locationsCount":43},"100649444","simplified-acute-physiology-score-2-and-pressure-ulcer-prediction-in-icu-100649444","NCT07732517","Simplified Acute Physiology Score 2 and Pressure Ulcer Prediction in ICU.","Using the Simplified Acute Physiology Score 2 (SAPS 2) for Predicting Pressure Ulcer Formation Among Critically Ill Patients Admitted in Medical Intensive Care Unit.","IGS-2-MIR","Inclusion Criteria:\n\nAdults ≥ 18 years of age; Patients admitted to intensive care unit; Patients without any preexisting pressure ulcer on admission; Capacity to give informed consent.\n\nExclusion Criteria:\n\nLength of stay less than 24 hours; Decline to participate in the study; Admission criteria being post-surgery monitoring and\u002For admission for drug intoxication Patients admitted to ICU with a pre-existent sacral pressure ulcer (any stage).",{"count":242,"type":23},500,"Critically ill patients admitted in intensive care units are at high risk of developing pressure ulcer (also known as pressure injury). In Bordeaux teaching hospital, a prevalence survey identified the department of anaesthesia and Intensive Care Unit with the highest rate for pressure ulcer (up to 29% of patients). Yet, developing a PU will increase patient's pain, health expenses, and the risks for further complications such as infection, prolonged hospitalization and a higher mortality rate. Therefore, this study aims at improving pressure ulcer prediction by using the Simplified Acute Physiology Score 2 (SAPS 2) as the latter estimates the severity of a patient condition while factoring in several causative factors for pressure ulcer among ICU patients. This could then lead to a better use and allocation of human and material resources and improve patients' care.",[245],"Pressure Ulcers",[247,248,249,250],"SAPS 2","Pressure ulcers","predictive test","Intensive Care Unit","2026-07-23",{"date":253,"type":35},"2026-07-29",{"date":255,"type":23},"2027-02",{"date":185,"type":23},{"name":41,"class":42},{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":55,"phases":268,"briefSummary":269,"conditions":270,"keywords":274,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":289},"100623143","age-accumulation-in-patients-on-long-term-parenteral-nutrition-100623143","NCT07392801","AGE Accumulation in Patients on Long-term Parenteral Nutrition","Study of Advanced Glycation End-products Accumulation in Patients Under Long-Term Parenteral Nutrition (NUPARAGE2)","NUPARAGE2","Inclusion Criteria:\n\n* Patients (adults and children, all ages) initiating long-term parenteral nutrition\n* Followed at CHU de Bordeaux or Robert Debré Hospital (APHP)\n* Covered by French Social Security system\n* Written informed consent obtained from patient (if adult) or legal guardian (if minor)\n\nExclusion Criteria:\n\n* Fitzpatrick skin type ≥ V (darker skin tones)\n* Forearm tattoos at the site of measurement\n* For patients included under 1 year of age: patients born prematurely (before 37 weeks of amenorrhea)\n* Pregnant or breastfeeding women.",{"count":267,"type":23},50,[57],"This prospective and observational study aims to evaluate the accumulation of advanced glycation end-products (AGEs) in adult and pediatric patients starting long-term parenteral nutrition, by non-invasive skin AGE measurements over a 12-month follow-up.",[271,272,273],"Chronic Intestinal Insufficiency","Advanced Glycation and Products","Parenteral Nutrition",[275,276,277,278,279,280,281],"parenteral nutrition","Advanced Glycation End Products","Oxidative Stress","Metabolic Diseases","Cardiovascular Diseases","Short Bowel Syndrome","chronic intestinal insufficiency",{"date":283,"type":35},"2026-07-24",{"date":285,"type":35},"2026-07-22",{"date":287,"type":23},"2028-07",{"name":41,"class":42},3,{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":298,"enrollmentInfo":299,"targetDuration":4,"studyType":55,"phases":301,"briefSummary":303,"conditions":304,"keywords":306,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":313,"completionDateStruct":314,"leadSponsor":316,"locationsCount":289},"100648755","phase-1-venetoclax-in-association-with-37-and-midostaurin-in-flt3-mutated-acute-myeloid-leukemia-100648755","NCT07726576","Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia","Phase 1\u002F2 Evaluating the Addition of Venetoclax to Standard 3+7 and Midostaurin Induction Treatment in Patients With FLT3-mutated Acute Myeloid Leukemia Eligible to Intensive Chemotherapy - MIDOVEN","MIDOVEN","Main inclusion criteria:\n\n1. Age ≥18 years and ≤70 years\n2. Newly diagnosed AML according to World Health Organization (WHO) 2022 classification\n3. Documented FLT3 gene mutation (-TKD D835 or I836 or -ITD or both) FLT3-ITD is assessed by DNA fragment analysis. Positivity is defined as an ITD\u002Fwt ratio of ≥ 0.05 (5%).\n\n   FLT3-TKD D835 or I836 is assessed by NGS. Positivity is defined as a VAF \\> 5%.\n4. Patient must be eligible for intensive chemotherapy.\n\nMain exclusion criteria:\n\n1. Prior treatment for AML or myelodysplastic (MDS) phase.\n2. Prior exposure to VEN or other BCL2 inhibitors\n3. AML secondary to prior hematological disorders, including myelodysplastic syndrome, myeloproliferative disorders and\u002For therapy-related AML.\n4. Acute promyelocytic leukemia, CBF-AML, Phi+ AML\n5. Significant active cardiac disease within 6 months prior to the start of study treatment or QTc interval using Fridericia's formula (QTcF) ≥ 450 msec.\n6. Cardiac ejection fraction \\\u003C45%","70 Years",{"count":300,"type":23},41,[302,87],"PHASE1","Acute myeloid leukemia (AML) with FLT3 mutation accounts for 30% of patients and is associated with a poor prognosis. Because of the FLT3 mutation, a tyrosine kinase inhibitor, midostaurin (MIDO), is added to the standard treatment with daunorubicin and cytarabine, from D8 to D21 of induction and of each consolidation cycle, followed by one year of maintenance. Venetoclax (VEN), a BCL2 inhibitor, has revolutionized the management of AML patients ineligible for intensive chemotherapy, in combination with azacitidine or cytarabine. The investigators hypothesize that a four-drug induction regimen (daunorubicin+cytarabine+MIDO+VEN) will increase complete remission (CR) rate without measurable residual disease (MRD) and improve event free survival (EFS), relapse free survival (RFS) and overall survival (OS) of this subgroup of patients with unmet medical need.",[305],"Leukemia, Myeloid, Acute",[307,308,309,310],"Acute myeloid leukemia","FLT3 mutation","midostaurin","venetoclax","2026-07-21",{"date":283,"type":35},{"date":101,"type":23},{"date":315,"type":23},"2031-12",{"name":41,"class":42},{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":324,"targetDuration":4,"studyType":55,"phases":325,"briefSummary":326,"conditions":327,"keywords":330,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":43},"100648276","abnormality-of-the-central-canal-of-the-spinal-cord-in-syringomyelia-in-a-patient-with-a-basal-skull-malformation-100648276","NCT07720206","Abnormality of the Central Canal of the Spinal Cord in Syringomyelia in a Patient With a Basal Skull Malformation","SYRCANAL","Inclusion Criteria:\n\n* Adult patients being treated for Chiari malformation or syringomyelia at Bordeaux University Hospital\n* Patients admitted for an initial surgical consultation regarding Chiari malformation with or without syringomyelia at Bordeaux University Hospital\n* Individuals enrolled in or covered by a social security program.\n* Free, informed, and express consent (confirmed in writing) (no later than the day of enrollment and prior to any examination required by the study).\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding patients\n* Contraindications to MRI\n* Individuals deprived of their liberty by judicial or administrative order,\n* Adults subject to legal protective measures (guardianship, conservatorship, judicial protection).\n* Patients who have previously undergone surgery for a Chiari malformation or a posterior fossa malformation",{"count":267,"type":23},[57],"The aim of this study is to analyze the association between a deformity of the cranial portion of the central spinal canal and syringomyelia in patients with a Chiari-type malformation of the craniocervical junction.\n\nThe investigators hypothesize that Chiari malformation, defined by the herniation of the cerebellar tonsils through the foramen magnum, may be responsible for a deformation of the cranial portion of the central spinal canal, and that this deformation is associated with the presence of syringomyelia in patients with this malformation.",[328,329],"Chiari Malformation Type I","Syringomyelia",[331,332,333,334,335],"Chiari malformation","spinal cord","central canal","MR","syringomyelia","2026-07-17",{"date":285,"type":35},{"date":339,"type":23},"2026-09-30",{"date":341,"type":23},"2029-09-30",{"name":41,"class":42},{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":367},"100647843","development-of-a-prediction-score-for-the-occurrence-of-death-or-lung-transplantation-in-patients-with-emphysema-secondary-to-alpha-1-anti-tripsin-deficiency-100647843","NCT07715617","Development of a Prediction Score for the Occurrence of Death or Lung Transplantation in Patients With Emphysema Secondary to Alpha-1-anti-tripsin Deficiency","FLARE","1. Inclusion criteria:\n\n   * diagnosed between 2010 and 2025\n   * in the pulmonology department\n   * diagnosis of emphysema and COPD secondary to alpha-1 antitrypsin deficiency ZZ, Znull, ZMalton, Z and rare mutations,\n   * emphysema according to the initial thoracic CT scan (+\u002F- 12 months after diagnosis).\n2. Exclusion criteria:\n\n   * Age \\\u003C18 years\n   * Patient opposed to the use of their data for research purposes\n   * Patient deprived of liberty by judicial decision\n   * Patient not affiliated with a social security scheme\n   * no CT scan available\n   * no lung function test available the year around CT scan",{"count":171,"type":23},"Emphysema linked to alpha-1-antitrypsin deficiency (DAAT): towards a better prediction of risks Emphysema caused by alpha-1-antitrypsin deficiency (DAAT) is a rare genetic disorder that can lead to serious complications, such as the need for a lung transplant or death, affecting up to 15% of patients. The only specific treatment available is a weekly infusion of alpha-1-antitrypsin (IV-AAT), an expensive and burdensome therapy.\n\nCurrently, there is no reliable model to predict the course of the disease in these patients. Our study, conducted in several French hospitals, aims to develop a prediction tool combining clinical, biological, functional data and advanced medical image analysis (lung CT). This model will make it possible to identify the most at-risk patients, in order to better adapt their care, anticipate transplant needs and avoid unnecessary treatments for low-risk patients.\n\nUltimately, this approach could also improve access to care for patients who need it most, while optimizing health system resources.",[353,354,355,356,357,358],"Alpha-1-antitrypsin Deficiency","Emphysema","Artificial Intelligence (AI)","Predictive Learning Models","Mortality Prediction","Lung Transplantation","2026-07-15",{"date":361,"type":35},"2026-07-20",{"date":363,"type":35},"2026-02-16",{"date":365,"type":23},"2031-03-16",{"name":41,"class":42},4,{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":374,"eligibilityCriteria":375,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":52,"enrollmentInfo":376,"targetDuration":4,"studyType":55,"phases":378,"briefSummary":379,"conditions":380,"keywords":383,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":389,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":395},"100645085","modeling-the-early-stages-of-autoimmunity-through-the-study-of-immunological-thrombocytopenic-purpura-and-juvenile-lupus-100645085","NCT07680010","Modeling the Early Stages of Autoimmunity Through the Study of Immunological Thrombocytopenic Purpura and Juvenile Lupus","Modeling the Early Stages of Autoimmunity Through the Study of Immunological Thrombocytopenic Purpura and Juvenile Lupus PRELUDE","PRELUDE","* Inclusion criteria:\n\n  * For patients :\n\n    * Child or adolescent with newly diagnosed ITP or SLE according to the specific definitions of ITP or SLE, prior to any treatment,\n    * Over 1 and under 18 years of age at diagnosis, weighing more than 7 kg.\n    * Written consent from parents or guardians,\n    * Patient affiliated to a social security scheme.\n  * For controls :\n\n    * Over 1 and under 18 years of age at diagnosis, weighing more than 7 kg.\n    * Follow-up in the day hospital at the Bordeaux University Hospital, for a condition that does not affect the immune system\n    * Matched on age,\n    * Written consent from parents or guardians,\n    * Patient affiliated to a social security scheme\n* Exclusion criteria:\n\n  * For patients :\n\n    * ITP secondary to a known cause: previous or concomitant immune deficiency, bone marrow or organ transplantation, other autoimmune disease, Evans syndrome (autoimmune hemolytic anemia or autoimmune neutropenia present at ITP diagnosis) or cancer with immunosuppressive therapy.\n    * Treatment with immunomodulation or immunosuppressants (including immunoglobulins, corticoids, hydroxychloroquine), started prior to inclusion (day of sampling).\n    * Pregnant women, women in labour and breastfeeding women\n  * For controls :\n\n    * Suffering from an immunological disease,\n    * Infection within fifteen days prior to inclusion,\n    * Immunomodulatory therapy.\n    * Pregnant women, women in labour and breastfeeding women",{"count":377,"type":23},105,[57],"Immunologic thrombocytopenic purpura (ITP) in children is a pre-lupus condition if associated with the presence of anti-nuclear antibodies (ANA), providing a unique model for understanding the natural history of autoimmunity, particularly that of systemic lupus erythematosus (SLE). The investigators will describe the shared and\u002For unique immunological pathways involved at diagnosis in 70 children with ITP and in 20 children with SLE, and compare them between ITP-ANA- (more often transient), ITP-ANA+ (pre-lupus condition, more often persistent) and SLE",[381,382],"Immune Thrombocytopenic Purpura ( ITP )","Systemic Lupus Erythematosus (SLE)",[384,385,386,387,388],"Children","Immunologic Thrombocytopenic Purpura","Anti-Nuclear Antibody","Systemic Lupus Erythematosus","Biomarkers",{"date":336,"type":35},{"date":391,"type":23},"2026-07",{"date":393,"type":23},"2033-10",{"name":41,"class":42},2,{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":55,"phases":405,"briefSummary":406,"conditions":407,"keywords":409,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":43},"100535078","tissue-immune-landscape-of-graft-versus-host-disease-after-allogeneic-stem-cell-transplantation-til-gvhd-100535078","NCT06247150","Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)","TIL-GVHD","Inclusion Criteria:\n\n* Patient \\> 18 yo ;\n* Having undergone an allogeneic stem cell tranplant ;\n* 2 groups of patients will be eligible\n* showing evidence of primary cGVHD or occuring after Donor Lymphocyte Infusion\n\n  * in the case of first occurrence of cGVHD, in the absence of any new systemic therapy ;\n  * in the case of recurrent cGVHD, steroid dose has to be below 15mg\u002Fday of Prednisone ;\n* Having read, understood and signed an informed consent of the study;\n* With social security affiliation;\n\nExclusion Criteria:\n\n* Patient below 18 yo or unable to give consent ;\n* Systemic therapy using steroids over 15mg\u002Fd of Prednisone ; and\u002For the use of other systemic agent introduced in the last month ;\n* Haemorrhagic risk of biopsy anticipated ;\n* Absence of patient agreement for the study",{"count":404,"type":23},70,[57],"Graft versus Host Disease (GVHD) is frequent after allogeneic stem cell transplantation (alloSCT). GVHD occurs following 2 patterns : acute GVHD (aGVHD) or chronic GVHD (cGVHD). The latter occurs in nearly 50% of patients and its pathogenesis remains poorly understood. Previous translational studies have delineated biological immune dysregulation involved in cGVHD and facilitated the development of new drug and therapeutic strategies. New aspects of T and B cells collaboration in the context of cGVHD using blood description of a key player called TFH, classicaly involved in germinal center reaction, were previously uncovered (Forcade et al, Blood 2016). Previous studies in the context of auto-immune inflammation (lupus nephritis) or organ transplant rejection, suggested that target tissue could contain accessory lymphoid structures (TLS). The description of such structures in cGVHD target tissue would give the opportunity to directly analyze immune key player involved the pathogenesis of cGVHD.",[408],"Chronic Graft Versus Host Disease",[410,411,412,413],"Chronic GVHD","Biopsy","TFH","Tertiary lymphoid structures",{"date":415,"type":35},"2026-07-16",{"date":417,"type":35},"2024-05-21",{"date":419,"type":23},"2028-06",{"name":41,"class":42},{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":18,"minAge":428,"maxAge":429,"enrollmentInfo":430,"targetDuration":4,"studyType":55,"phases":431,"briefSummary":432,"conditions":433,"keywords":435,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":43},"100579498","performance-of-lung-mri-combined-to-synthetic-ct-in-the-follow-up-of-lung-nodules-100579498","NCT06825078","Performance of Lung MRI Combined to Synthetic CT in the Follow-up of Lung Nodules","NODU-MR","Inclusion Criteria:\n\n* Subject aged between 55 and 74 years\n* High risk of developing lung cancer: by a combination of exposure to lung carcinogens and smoking (exposure to tobacco at the rate of 30 packs\u002Fyear or cessation \\\u003C 15 years)\n* Presence of at least one lung solid nodule ≥ 5mm on the initial scan.\n* Subject able and willing to complete all scheduled visits and assessments.\n* Subject with health insurance.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Subject with signs of lung cancer\n* Subject with history of lung cancer\n* Presence of severe life-threatening comorbidities at 6 months (recent CVA, recent discovery of advanced stage cancer)\n* Subject who had already undergone a chest scan less than a year previously\n* No exposure to occupational lung carcinogens according to the predefined criteria.\n* No exposure to tobacco or insufficient exposure to tobacco or cessation \\> 15 years.\n* Contra-indication to MRI (Pace maker, implants, claustrophobia…)\n* Pregnant or breastfeeding woman\n* Poor understanding of French\n* Subject under legal protection","55 Years","74 Years",{"count":267,"type":23},[57],"Lung cancer screening trials using low-dose chest CT scans have shown a significant reduction of cancer related mortality in subjects at high risk of lung cancer. However, high rate of false positives and overdiagnosis have led to invasive methods, which are not without risks. Evaluation of lung nodules using lung MRI with ultra short echo time sequences (UTE) has been found comparable to chest CT scans. Moreover, MRI has the advantage of multiparametric characterization of lesions using different tissue contrasts. Following the recommendation of the French National Authority for Health (HAS) to evaluate new methods of lung cancer screening, this prospective single center pilot study is designed to evaluate the performance of multiparametric lung MRI combined to synthetic CT in the diagnosis of lung cancer in heavily smokers or ex-smokers professionally exposed to carcinogens",[434],"Lung Cancer",[436,437,438,439,440],"lung cancer screening","nodule","multiparametric lung MRI","low-dose chest CT","artificial intelligence","2026-07-08",{"date":229,"type":35},{"date":444,"type":35},"2025-02-12",{"date":446,"type":23},"2029-02",{"name":41,"class":42},{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":18,"minAge":455,"maxAge":456,"enrollmentInfo":457,"targetDuration":4,"studyType":55,"phases":459,"briefSummary":460,"conditions":461,"keywords":463,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":473},"100490746","neuro-cardiac-rehabilitation-in-youth-with-congenital-heart-disease-qualineurorehab-100490746","NCT05670132","Neuro-cardiac Rehabilitation in Youth With Congenital Heart Disease (QUALINEUROREHAB)","Impact of a Neuro-cardiac Rehabilitation Program on the Quality of Life of Children, Adolescents, and Young Adults With Congenital Heart Disease: the Multicentre Randomized Controlled QUALINEUROREHAB Trial","Inclusion Criteria:\n\n1. Patient with a CHD of moderate to great complexity as defined in the 2019 AHA\u002FACC guidelines (Appendix 2)85.\n2. History of cardiac surgery and\u002For catheter-based cardiac intervention(s) during the first year of life.\n3. Age between 8 and 25 years at the time of enrolment.\n4. Parental or legal guardian's consent for minors (\\\u003C18 years) and personal consent for adults.\n5. Social security affiliation (for France only)\n\nExclusion Criteria:\n\n1. Unstable and\u002For severe heart failure: severe heart failure (class IV NYHA functional class), recent decompensated heart failure requiring hospitalisation and\u002For any significant change in medication (\\\u003C 3 months before enrolment), systolic ventricle dysfunction (left ventricle or systemic ventricle ejection fraction \\\u003C 50%)82.\n2. Severe hypoxaemia: pulse oxygen saturation (SpO2) at rest \\\u003C85%, and\u002For SpO2 at exercise \\\u003C80%, and\u002For patient requiring oxygen therapy.\n3. Pulmonary hypertension as defined by the 2020 ESC guidelines, whatever the aetiology83.\n4. Significant systolic right ventricle (sRV) hypertension (sRV pressure \\> 50% of systemic systolic pressure).\n5. Uncontrolled arrhythmia: symptomatic treated or untreated arrhythmia at rest and\u002For exercise, treated arrhythmia with sustained supraventricular or ventricular tachycardia on ECG monitoring or during exercise and\u002For CPET, occurrence or aggravation of any supraventricular or ventricular arrhythmia during exercise and\u002For CPET.\n6. Advanced atrioventricular block (degree 2 or 3), occurrence or aggravation of any conduction disorder during exercise and\u002For CPET.\n7. Uncontrolled arterial hypertension at rest (e.g. if the blood pressure at rest during the consultation \\>140\u002F90 mmHg in adults, \\>95th percentile in children84).\n8. Acute or recent (\\\u003C 3 months) myocarditis and pericarditis.\n9. Symptomatic aortic or sub-aortic stenosis (mean gradient \\> 50 mmHg).\n10. Non-corrected coarctation of the aorta (surgical or catheter-based repair) with a clinical systolic gradient \\> 20 mmHg.\n11. Dilatation of the aorta (aortic root \\> 40 mm in adults, \\> 2 Z-score in children85 (http:\u002F\u002Fwww.parameterz.com\u002Fsites\u002Faortic-root) except in the case of repaired congenital heart disease with dilatation of the aorta inherent in the malformation and without significant risk of aortic dissection (tetralogy of Fallot, pulmonary atresia with VSD, transposition of the great arteries, truncus arteriosus, double outlet right ventricle, or single ventricle).\n12. Severe hypertrophic obstructive cardiomyopathy.\n13. Acute systemic illness.\n14. Recent (\\\u003C3 months) intracardiac thrombus, embolism, or thrombophlebitis.\n15. Inability to follow instructions and\u002For complete the questionnaires, as determined by the investigator.\n16. Absolute contraindications for CPET: fever, uncontrolled asthma, respiratory failure, acute myocarditis or pericarditis, uncontrolled arrhythmias causing symptoms or haemodynamic compromise, uncontrolled heart failure, acute pulmonary embolus or pulmonary infarction, and patients with mental impairment leading to inability to cooperate.\n17. Inability to undergo the physical intervention: inability to physically exercise, any invasive medical intervention occurring within 6 months preceding the enrolment or scheduled during the 12-month study period (such as cardiac surgery, catheter-based intervention, orthopaedic surgery, chemotherapy for cancer, or any other significant medical treatment or intervention, as determined by the investigator).\n18. Patient with a previously diagnosed or suspected severe psychiatric disorder (major depression with or without suicidal ideation, psychotic diagnoses, severe anxiety \u002Fpanic disorders) requiring hospitalization and\u002For continuous specialized care by a psychiatrist, as determined by the investigator.\n19. Patients who benefited from a cardiac rehabilitation within the 12 months preceding the enrolment.\n20. Patients who benefited from a computerized executive function or attention training such as Cogmed Working Memory Program within the 12 months preceding the enrolment.\n21. For female patients: pregnancy, pregnancy plan, or breastfeeding woman following questioning of the patient.\n22. Patients deprived of liberty due to an ongoing legal procedure, adult's patient under guardianship or curatorship or unable to personally express their consent.\n23. Any other clinical and\u002For pharmacological treatment that is believed to interfere with the study or the optimal clinical care.\n24. Initiation or total withdrawal of psychotropic medication (i.e., any psychotropic medication including methylphenidate, benzodiazepines, and mood stabilizers) within the 6 months preceding the enrolment.\n25. Patient participating or wishing to participate in any interventional clinical research (drug trial, medical device, non-drug trial).","8 Years","25 Years",{"count":458,"type":23},192,[57],"Remarkable progress in paediatric cardiology and surgery have led to the substantial increase of congenital heart disease (CHD) survivors. Long-term outcomes in rare and complex CHD have become a critical priority as three major sources of morbidity have been identified in this population: neurodevelopmental sequelae, mental health issues and reduced exercise capacity. These challenges adversely affect their quality of life and constitute a major public health issue. We seek to evaluate the efficacy of the first integrative and holistic program in Neuro-Cardiac Health associating physical and psychological rehabilitation for children with rare CHD compared to the standard of care. Children randomly assigned to the intervention will undergo a 12-week neuro-cardiac intervention including home-based adaptive physical exercise, telehealth parent and child psycho-education and child computerized cognitive training, as well in-person individual sessions of intervention reinforcement. Parents will be actively involved and will receive personalized feedback and educational resources. Children assigned to the control group will receive the standard of care in congenital cardiology. Post-intervention effects will be measured after 12-months on several outcomes including health-related quality of life (HRQoL), trained and untrained cognitive skills, mental health outcomes and cardiovascular\u002Fphysical variables.",[462],"Congenital Heart Disease",[464,465],"Neuro-cardiac rehabilitation program","Quality of life","2026-07-07",{"date":441,"type":35},{"date":469,"type":35},"2024-06-03",{"date":471,"type":23},"2028-06-03",{"name":41,"class":42},6,{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":482,"enrollmentInfo":483,"targetDuration":4,"studyType":55,"phases":485,"briefSummary":486,"conditions":487,"keywords":490,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":503},"100446843","phase-2-preventive-effect-of-clopidogrel-on-the-systemic-sclerosis-development-risk-100446843","NCT05098704","Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk","Phase II\u002FIII Double-blind Randomized Placebo-controlled Trial Assessing the Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk in Subjects With Specific Dysimmunity and Raynaud Phenomenon","PSSIT","Inclusion Criteria:\n\n* Patient over 18 years old, and less than 85 years old.\n* Patient with positive AAN (AAN ≥ 1\u002F160) with the following specificity: anti-Scl70 or anti-centromere or anti-RNApolIII, or any other auto-antibodies related to systemic sclerosis\n* Patient with RP reported by the subject and confirmed by the physician.\n* Patient affiliated to a health insurance system.\n* Patient who accepts to participate to the study and signs an inform consent form.\n\nExclusion Criteria:\n\n* Patient with an SSc diagnosis according to ACR\u002FEULAR 2013 criteria.\n* Patient with skin fibrosis at screening.\n* Patient with antiplatelet treatment at screening.\n* Patient with contraindications to clopidogrel.\n* Patient treated by immunosuppressive agent at screening.\n* Patient treated by anticoagulants at screening\n* Pregnant or breastfeeding women.\n* Women of childbearing age refusing effective contraception method during the study treatment (24 months).\n* Incompetent adults (i.e. Individuals under the protection of a conservator)","85 Years",{"count":484,"type":23},90,[87,173],"Systemic sclerosis (SSc) is a severe autoimmune disease associating dysimmunity, vasculopathy and fibrosis. No curative treatment is available. Pre-clinical abnormalities can be found such as specific autoantibodies. The association of Raynaud phenomenon and SSc-specific anti-nuclear antibodies is the hallmark of pre-scleroderma subjects, among who around 47% declare a complete disease after five years. The aim of this study is to assess in this particular population the preventive effect of an anti-platelet treatment.",[488,489],"Scleroderma","Systemic Sclerosis",[491,492,493,494,495],"systemic sclerosis","clopidogrel","platelet","prevention","primary care","2026-07-03",{"date":466,"type":35},{"date":499,"type":35},"2022-06-22",{"date":501,"type":23},"2032-06",{"name":41,"class":42},11,{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":508,"acronym":509,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":18,"minAge":511,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":55,"phases":514,"briefSummary":515,"conditions":516,"keywords":520,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":43},"100644894","sage-heart--senior-assessment-fragility-and-post-operative-qalys-1-year-after-emergency-heart-surgery-for-patients-aged-75-and-older-100644894","NCT07677319","SAGE-Heart : Senior Assessment fraGility and Post-opErative QALYs 1 Year After Emergency HEART Surgery for Patients Aged 75 and Older","SAGE-Heart","Inclusion Criteria:\n\n* Patients aged ≥ 75 years who are affiliated with or beneficiaries of a social security scheme and undergoing emergency cardiac surgery under cardiopulmonary bypass, either immediate or urgent (relative) :\n\n  * Immediate emergency surgery: intervention performed before the start of the next working day following the decision to operate,\n  * Urgent (relative) emergency surgery: patients not admitted electively for surgery but requiring an intervention during the current hospital stay for medical reasons, and who cannot be discharged without undergoing a definitive procedure\n\nExclusion Criteria:\n\n* Patients requiring preoperative cardiopulmonary resuscitation\n* Scheduled (elective) surgery\n* Lack of informed consent\n* Impaired consciousness at the time of inclusion (defined by a Glasgow Coma Scale score \\\u003C 15)\n* Individuals under legal guardianship or judicial protection\n* Individuals participating in another interventional research protocol","75 Years",{"count":513,"type":23},265,[57],"The hypothesis is that the preoperative Clinical Frailty Score (CFS) is a predictive factor for a loss in quality-adjusted life years (QALYs) one year after emergency cardiac surgery under cardiopulmonary bypass (CPB) in patients aged 75 years and older.",[517,518,519],"Frailty","Cardiac Surgery","QALYs",[517,521,518,522,519,523,524],"Elderly","Cardio-pulmonary Bypass","Clinical Frailty Scale","EuroQol, postoperative","2026-06-29",{"date":527,"type":35},"2026-06-30",{"date":529,"type":35},"2025-12-03",{"date":531,"type":23},"2028-12-03",{"name":41,"class":42},{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":538,"acronym":122,"eligibilityCriteria":539,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":540,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":542,"conditions":543,"keywords":545,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":558},"100308304","uroccr-database-french-research-network-for-kidney-cancer--uroccr-100308304","NCT03293563","UroCCR Database: French Research Network for Kidney Cancer -UroCCR","UroCCR Database: French Research Network for Kidney Cancer (National Multidisciplinary Clinical and Biological Database on Kidney Cancer)","Inclusion Criteria:\n\n* Adult patient with kidney cancer\n* Patient with no opposition to collection of its data for the study\n\nExclusion Criteria: none",{"count":541,"type":23},30000,"Kidney cancer management has become increasingly complex with the diversification of treatment options and the integration of multidisciplinary care. To meet these challenges, the UroCCR network was established in France as a national registry and research platform dedicated to renal cancer. Funded by the French National Cancer Institute (INCa), UroCCR prospectively collects comprehensive real-world data on patient care and disease evolution, while systematically linking these records with annotated biological samples (plasma, urine, and both healthy and tumour tissues). For each case, more than one thousand variables may be recorded, covering clinical, imaging, and patient-reported information.\n\nMore than a registry, UroCCR is a collaborative network of clinical and research professionals using a shared, evolving tool that supports rapid implementation of studies and fosters active knowledge generation. Unlike retrospective registries or sample-centred biobanks, UroCCR offers prospective, patient-focused inclusion and a wide scope of investigation-from translational and technological research to clinical evaluation and social sciences. It also supports multiple ancillary studies, including retrospective analyses and prospective clinical or observational trials, and operates under a structured governance system with recognised national and international labels.\n\nBy combining a rigorously structured, multicentre dataset with linkage to the French national health data system (SNDS), the platform uniquely unites detailed clinical annotation with population-wide coverage, creating a high-value environment for advancing kidney cancer research and care.",[544],"Kidney Cancer",[546,547,548,549],"Kidney cancer","Surgical approaches","Medical treatment","Multicentric and multidisciplinary network","2026-06-22",{"date":552,"type":35},"2026-06-25",{"date":554,"type":4},"2011-12",{"date":556,"type":23},"2040-12",{"name":41,"class":42},68,{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":563,"acronym":564,"eligibilityCriteria":565,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":566,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":568,"conditions":569,"keywords":572,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":579,"leadSponsor":581,"locationsCount":43},"100644207","jugular-gating-for-upright-level-adjustment-and-targeted-enhancement-of-cerebral-perfusion-100644207","NCT07665606","JUgular Gating for Upright Level Adjustment and Targeted Enhancement of Cerebral Perfusion","JUGULATE","Inclusion Criteria:\n\n* Patients ≥ 18 years old\n* Hospitalized in the neurocritical care unit or the trauma unit\n* Scheduled for nursing care requiring a supine position.\n* Arterial catheter allowing continuous measurement of mean arterial pressure.\n* Central venous catheter for continuous measurement of central venous pressure.\n* External ventricular drain or intracranial pressure sensor for intracranial pressure monitoring.\n* Bed with controlled inclination capability.\n* Clinically stable condition allowing transient positional changes (as judged by the clinician).\n* Not included, or planned to be included in another trial.\n\nExclusion Criteria:\n\n* Contraindication to trunk mobilization.\n* Being a minor or placed under supervision.\n* Hemodynamic or respiratory instability.\n* Uncontrolled intracranial hypertension, refractory arterial hypertension, or severe dysautonomia.\n* Pregnancy or breastfeeding.\n* Refusal to participate in the study.",{"count":567,"type":23},30,"Investigators aim to demonstrate that the evolution of intracranial pressure (ICP) is nonlinear and may be influenced by jugular vein collapse. This collapse is estimated to occur at the angle where the hydrostatic pressure of the blood column matches the central venous pressure, and it can be assessed using ultrasonography. This approach allows for the determination of an individualized tilt angle, optimizing cerebral perfusion pressure without compromising venous drainage.",[570,571],"Intracranial Pressure","Critical Care",[570,573,574],"jugular vein collapse","Critical care","2026-06-18",{"date":577,"type":35},"2026-06-24",{"date":37,"type":23},{"date":580,"type":23},"2027-03-31",{"name":41,"class":42},{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":17,"sex":18,"minAge":590,"maxAge":591,"enrollmentInfo":592,"targetDuration":4,"studyType":55,"phases":594,"briefSummary":595,"conditions":596,"keywords":598,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":604,"startDateStruct":605,"completionDateStruct":606,"leadSponsor":607,"locationsCount":395},"100644164","advancing-neurogenetic-diagnoses-through-long-read-sequencing-100644164","NCT07665554","Advancing Neurogenetic Diagnoses Through Long-Read Sequencing","NRGEN-NGS3 : Advancing Neurogenetic Diagnoses Through Long-Read Sequencing","NRGEN-NGS3","Inclusion Criteria:\n\n* All participants :\n\n  * Participants affiliated with or beneficiaries of a social security scheme\n  * Participants who speak French\n  * Participants aged ≥ 6 and ≤ 60 years\n* For patients requiring a new sample:\n\n  * Free and informed consent, signed by the parents or the holder of parental authority for patients under the age of 18\n  * Free and informed consent, signed by the patient's representative for adults under guardianship\n  * Free and informed consent, signed by the adult patient\n* For diagnosed patients :\n\n  • DeoxyriboNucleic Acid (DNA) sample from a subject carrying a nucleotide repeat expansion in one of the selected genes.\n  * DNA available in sufficient quantity (5-10 µg) or patient agreeing to a blood draw from which DNA will be extracted.\n  * DNA extraction methods known and validated by the steering committee (see paragraph 7).\n* For participants from undiagnosed families :\n\n  o Index cases:\n\n  • Patient affected by a neurological disease candidate for these repeats, for which genomic data did not reveal mutations or expansions in known genes.\n  * Patient whose DNA is already available and whose extraction method is known and validated by the steering committee or patient whose DNA is not available but who agrees to a blood draw.\n  * Patient willing to undergo a skin biopsy if not previously obtained.\n  * Patient with no family members affected by any of the neurological diseases candidate for these repeats, i.e., genomic data do not reveal mutations or expansions in known genes.\n  * Patient from a family in which at least one affected and one unaffected member agree to partici-pate in the study by providing a sample, or whose DNA is already available and extracted using a method known and validated by the steering committee.\n\n    * For all related members of undiagnosed families who have agreed to participate:\n  * Have at least two other family members who have agreed to participate in the study.\n  * Agree to provide a blood sample or have DNA already available in sufficient quantity and extracted using a method known and validated by the steering committee.\n  * Patient willing to undergo a skin biopsy if not previously obtained.\n  * Be affected by a neurological disease candidate for these repeats, for which genomic data did not reveal mutations or expansions in known genes, or be unaffected and have had a neurological examination showing no signs related to any of the neurological diseases candidate for these repeats.\n* For controls :\n\nParticipant for whom:\n\n* a consultation is scheduled at CHU Bordeaux for a reason other than a neurological disorder, has agreed to a neurological examination showing no signs of neurological disease, and has agreed to a blood draw and skin biopsy, or\n* the samples required for the study are already available in sufficient quantity in the CHU Bordeaux biobank and extracted using a method known and validated by the steering committee, or\n* accompanying a patient attending a consultation at CHU Bordeaux, showing no signs of neurologi-cal disease, and agreeing to a blood draw and skin biopsy, or whose samples are already available in sufficient quantity and extracted using a method known and validated by the steering committee.\n\nExclusion Criteria:\n\nFor all participants:\n\n• Refusal to participate in research: Refusal to provide informed consent or opposition to the use of these samples.\n\n* By the parents or the holder of parental authority for patients under the age of 18\n* By the patient's representative for adults under guardianship\n* By the adult patient This opposition from the patient must be communicated to the site investigator within a maximum of one month after the information note has been sent. If the letter confirming consent is returned due to an incorrect address, the patient will not be included.\n\n  * Degraded DNA or average size \\\u003C 30 kb","6 Years","60 Years",{"count":593,"type":23},304,[57],"Nucleotide repeats emerge as one of the most prolific classes of genetic variations. They have the propensity to in-crease in length across generations, and have been implicated in at least 65 known neurological\u002F neurodevelop-mental and neuromuscular conditions. Simultaneous analysis of all these nucleotide repeats is now possible through the cutting-edge methodologies recently developed that are the long-read sequencing and the optical genome mapping. Investigator propose to test these methodologies in patients carrying expansions in those repeats and to determine the capacity of these technics to detect novel repeats in patients with no genetic diagnosis yet.",[597],"Neurogenetic Diseases",[599,600,601,602,603],"long read sequencing","genetic diagnosis","cytogenetics","nucletotide repeat expansion","neurogenetic disease",{"date":577,"type":35},{"date":101,"type":23},{"date":185,"type":23},{"name":41,"class":42},{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":614,"eligibilityCriteria":615,"healthyVolunteers":17,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":616,"targetDuration":4,"studyType":55,"phases":618,"briefSummary":619,"conditions":620,"keywords":629,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":639,"startDateStruct":640,"completionDateStruct":641,"leadSponsor":643,"locationsCount":43},"100644109","morphology-in-oral-rare-syndromes--artificial-intelligence-for-clinical-diagnosis-100644109","NCT07666269","Morphology in Oral Rare Syndromes & Artificial Intelligence for Clinical Diagnosis","Geometric Morphometric Characterization of Oro-Dental Anomalies in Rare Bone and Cartilage Diseases From 3D Digital Data (MOSAIC)","MOSAIC","Inclusion Criteria:\n\n* For cases: Diagnosis of a rare bone and cartilage disorder confirmed by the Rare Disease Competence Center for Constitutional Bone Disorders (MOC) or Calcium and Phosphate Metabolism Disorders (CaP), genetically and\u002For clinically.\n* Ability to undergo a 3D intra-oral scan;\n* Ability of the participant to understand the information notice provided regarding the use of their medical data and 3D digital models for research purposes, and to express informed non-objection to participation in the research.\n* For controls: healthy adults recruited in the Dental Medicine Department.\n\nExclusion Criteria:\n\n* History of major orthodontic\u002Forthognathic treatment;\n* Craniofacial conditions unrelated to the studied diseases (e.g., cleft palate, non-target craniofacial syndromes);\n* Impossibility to obtain a 3D optical impression;\n* Refusal or inability of the participant to understand the information notice and\u002For to express informed non-objection to participation in the research.",{"count":617,"type":23},240,[57],"MOSAIC aims to determine whether oro-dental morphological anomalies, particularly palatal morphology, associated with rare bone and cartilage diseases can be precisely characterized using 3D digital models analysed through geometric morphometrics. The study will also evaluate whether these morphological signatures can train an artificial intelligence (AI) algorithm to classify syndromes. A prospective monocentric case-control cohort will be constituted, including 3D intra-oral scans and associated clinical data. The final goal is to improve diagnostic accuracy and reduce diagnostic delay in rare bone disorders.",[621,622,623,624,625,626,627,355,628],"Osteogenesis Imperfecta","Rare Bone Disorders","Hypophosphatemia","X-Linked","Mucopolysaccharidoses","Tooth Abnormalities","Palate; Deformity","Machine Learning",[630,631,632,633,634,440,635,636,637,638],"Rare bone diseases","palatal morphology","geometric morphometrics","3D intra-oral scan","machine learning","diagnostic classification","osteogenesis imperfecta","X-linked hypophosphatemia","mucopolysaccharidosis",{"date":577,"type":35},{"date":37,"type":23},{"date":642,"type":23},"2028-03-01",{"name":41,"class":42},{"id":645,"slug":646,"hasResults":12,"nctId":647,"briefTitle":648,"officialTitle":649,"acronym":650,"eligibilityCriteria":651,"healthyVolunteers":12,"sex":18,"minAge":590,"maxAge":652,"enrollmentInfo":653,"targetDuration":4,"studyType":55,"phases":655,"briefSummary":656,"conditions":657,"keywords":659,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":662,"startDateStruct":663,"completionDateStruct":665,"leadSponsor":667,"locationsCount":668},"100511313","intestine-lung-axis-of-cystic-fibrosis-patients-treated-with-the-combination-elexacaftortezacaftorivacaftor-100511313","NCT05937815","Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor\u002FTezacaftor\u002FIvacaftor","Monitoring of the Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor\u002FTezacaftor\u002FIvacaftor: Study of the Pulmonary and Gut Microbiota and Inflammation","KAF-BIOTA","Inclusion Criteria:\n\n* To have cystic fibrosis (sweat test \\> 60 mmol\u002Fl);\n* Carrier of at least one DeltaF508 mutation;\n* Be followed in the current care by a participant in the CRCM study;\n* Start treatment with elexacaftor\u002Ftezacaftor\u002Fivacaftor in routine care, according to the indications in the Marketing Authorization at the time of inclusion;\n* Be of the age specified in the marketing authorization in force;\n* Person affiliated or beneficiary of a social security scheme;\n* Consent obtained by the patient (for adult patients) or the holders of parental authority (for minor patients) before any examination required by the research and oral and\u002For written consent by the participant (depending on his or her age) .\n* Patient agreeing to take part in cohort follow-up studies of patients treated with elexacaftor\u002Ftezacaftor\u002Fivacaftor, included in the French cystic fibrosis register (cf. Study by Pr BURGEL and\u002For MODUL CF).\n\nExclusion Criteria:\n\n* Start of treatment with elexacaftor\u002Ftezacaftor\u002Fivacaftor as part of a therapeutic trial.\n* Patient already on CFTR modulator (including lumacaftor\u002Fivacaftor)\n* Vulnerable people (pregnant woman, person under guardianship\u002Fcurators)","17 Years",{"count":654,"type":23},253,[57],"Cystic fibrosis is a systemic disease, which affects in particular the respiratory and digestive systems of patients, sites of chronic inflammation.\n\nA new combination of elexacaftor\u002Ftezacaftor\u002Fivacaftor has proven its efficacy for the treatment of patients aged 12 years and over with two F508del mutations or a so-called \"minimal function\" mutation associated with one F508del mutation. European marketing authorization was obtained in August 2020 and access in France should therefore arrive soon. Given that this treatment targets new mutations and that the efficacy seems greater than with LUM\u002FIVA, it is important to assess its impact on the microbiota and the pulmonary and digestive inflammation of patients.\n\nIt is therefore a question of taking advantage of the experience of the Lum-Iva-Biota cohort, and the validated and operational sample circuit established in the various participating centers to set up a biological collection for the collection and storage of sputum and stools of patients during the first year of treatment with elexacaftor\u002Ftezacaftor\u002Fivacaftor, in order to study the effect of treatment on the lung and digestive microbiota\u002Fmycobiota and inflammation.",[658],"Cystic Fibrosis",[660,661],"elexacaftor\u002Ftezacaftor\u002Fivacaftor","lung and digestive microbiota and inflammation",{"date":550,"type":35},{"date":664,"type":35},"2021-09-13",{"date":666,"type":23},"2026-09-13",{"name":41,"class":42},15,{"id":670,"slug":671,"hasResults":12,"nctId":672,"briefTitle":673,"officialTitle":674,"acronym":675,"eligibilityCriteria":676,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":677,"targetDuration":4,"studyType":55,"phases":679,"briefSummary":680,"conditions":681,"keywords":685,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":694,"lastUpdatePostDateStruct":695,"startDateStruct":696,"completionDateStruct":698,"leadSponsor":700,"locationsCount":701},"100548793","combined-platelet-and-erythrocyte-autotransfusion-during-cardiac-surgery-coltrane-trial-100548793","NCT06425614","COmbined pLaTelet and eRythrocyte AutotransfusioN During Cardiac surgEry (COLTRANE) Trial","Centrifugation-based Versus Filtration-based Intraoperative Cell Salvage on Quality of Perioperative Haemostasis in Cardiac Surgery: A Randomized Clinical Trial","COLTRANE","Inclusion Criteria:\n\nAdult patients (≥18 yr) affiliated or beneficiary of a social security scheme and undergoing on-pump cardiac surgery at high risk for bleeding with autotranfusion indication defined as:\n\n* Primary or redo combined cardiac procedures (2 valves or more, valve(s) and coronary artery bypass grafting(s))\n* Primary or redo ascending aorta surgery\n* Primary or redo isolated coronary artery bypass grafting (iCABG) involving 3 or more grafts using the internal mammary artery\n* Free, informed and written consent signed by the participant and the investigator\n\nExclusion Criteria:\n\n* Preoperative therapy by P2Y12 receptor inhibitors (within 5 preoperative days for clopidogrel, ticagrelor or ticlopidine, within 7 preoperative days for prasugrel, and within one preoperative hour for cangrelor)\n* Preoperative treatment by active anticoagulant drug (within 5 preoperative days for VKA, 4 days for dabigatran, 3 days for rivaroxaban and apixaban, 24 hours for therapeutic LMWH, 36 hours for therapeutic fondaparinux, 12 hours for prophylactic LMWH, 24 hours for prophylactic fondaparinux, 4 hours for unfractionated heparin Sepsis\n* Malignant tumor\n* Immunocompromised patients (steroids, immunosuppressive drugs, ongoing treatment for solid tumor or hematologic malignancy, primary immunodeficiency disorders, AIDS)\n* Emergency cardiac surgery\n* Heart transplantation\n* Implantation or patients under ventricular assist device (VAD)\n* Patients with two or more previous sternotomy\n* Surgery procedure requiring circulatory arrest and\u002For profound hypothermia (\\\u003C32°C)\n* Active infective endocarditis\n* Cardiac surgical procedure for benign or malignant cardiac tumors\n* Patients with known acquired or constitutional coagulopathy requiring specialist management\n* End stage renal disease\n* Preoperative haemoglobin level less than 10 g\u002FdL\n* Preoperative platelet count \\\u003C 100 G\u002FL\n* Persons participating in another interventional research including a period of exclusion that is still ongoing\n* Pregnant or breastfeeding women\n* Persons placed under judicial protection\n* Patients deprived of liberty",{"count":678,"type":23},570,[57],"Despite significant advances in patient blood management, cardiac surgery remains a surgical procedure at high risk for bleeding. Numerous perioperative blood conservation strategies have been developed for limiting the use of blood products. Among them, the processing of shed blood and residual cardiopulmonary bypass circuit volume with autotransfusion device is routinely used. Conventional centrifugation-based autotransfusion devices actually available only recover red blood cells while platelets and coagulation factors are almost totally lost. Consequently, large amounts of intraoperative cell salvage could significantly alter perioperative haemostasis. The SAME autotransfusion device (i-SEP, France) is a new and innovative filtration-based autotransfusion device able to recover erythrocytes, leukocytes but also platelets. By offering the opportunity to re-infuse to patients their own platelets in addition red blood cells, significantly improve perioperative haemostasis with this new device is expected. The purpose of the COLTRANE trial is to compare the quality of the perioperative haemostasis in cardiac surgical patients for whom intraoperative cell salvage will be performed using either the SAME autotransfusion device or conventional centrifugation-based device.\n\nBecause allogenic transfusion of blood products as well as surgical re-exploration for excessive bleeding are associated with poor outcomes and prolonged length of stay, the use of filtration-based SAME device by maintaining perioperative haemostasis could improve outcomes and reduce length of stay of high risk patients. The fact that patients receive their own platelets should also limit the risk of allo-immunization and immunomodulation which is recognized as one of the underlying mechanisms of perioperative increased risk of infection.",[682,683,684],"On-pump Cardiac Surgery","High Risk for Bleeding","Autotransfusion",[686,687,688,689,690,691,692,693],"cardiac surgery","bleeding","autotransfusion","cardiopulmonary bypass","perioperative haemostasis","Universal Definition of Perioperative Bleeding","filtration-based autotransfusion","centrifugation-based autotransfusion","2026-06-09",{"date":71,"type":35},{"date":697,"type":35},"2024-07-15",{"date":699,"type":23},"2027-02-15",{"name":41,"class":42},10,""]